Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07130383) titled 'A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors' on Aug. 12.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd
Condition:
Advanced Breast Cancer
Advanced Malignant Solid Tumor
Intervention:
Drug: MHB036C for Injection
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: September 2025
Target Sample Size: 210
To know more, visit https://c...